Drug Type Small molecule drug |
Synonyms Alflutinib, Firmonertinib, Furmonertinib + [7] |
Mechanism EGFR T790M inhibitors(EGFR T790M inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 20 inhibitors(EGFR exon 20 Mutation inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date CN (03 Mar 2021), |
RegulationBreakthrough Therapy (US), Orphan Drug (US), Priority Review (CN), Breakthrough Therapy (CN), Conditional marketing approval (CN) |
Molecular FormulaC29H35F3N8O5S |
InChIKeyWDPGHXINXNBHAS-UHFFFAOYSA-N |
CAS Registry2130958-55-1 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
EGFR ex20ins mutation in non-small cell lung cancer | CN | 28 Jun 2022 | |
EGFR T790M Mutation Positive Non-Small Cell Lung Carcinoma | CN | 03 Mar 2021 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Non-squamous non-small cell lung cancer | Phase 3 | US | 18 May 2023 | |
Non-squamous non-small cell lung cancer | Phase 3 | JP | 18 May 2023 | |
Non-squamous non-small cell lung cancer | Phase 3 | AU | 18 May 2023 | |
Non-squamous non-small cell lung cancer | Phase 3 | FR | 18 May 2023 | |
Non-squamous non-small cell lung cancer | Phase 3 | NL | 18 May 2023 | |
Non-squamous non-small cell lung cancer | Phase 3 | ES | 18 May 2023 | |
EGFR positive non-small cell lung cancer | Phase 3 | CN | 30 May 2019 | |
metastatic non-small cell lung cancer | Phase 3 | CN | 30 May 2019 | |
Adenocarcinoma of Lung | Phase 2 | - | 01 Aug 2021 | |
EGFR-mutated non-small Cell Lung Cancer | Phase 1 | US | Arrivent BioPharma, Inc.Startup | 30 Jun 2022 |
Phase 3 | 257 | araexqcfhp(etqbzpfsjk) = yeveiquypv wrtegsruyu (llxxqntxjn ) | Positive | 17 Jun 2024 | |||
- | |||||||
Not Applicable | 48 | Furmonertinib 240mg | mhmakqgfak(jqvzmbucnk) = zzlwxaspfz ncdmxgmwpi (syyuyjkklz, 5.481-11.386) View more | Positive | 24 May 2024 | ||
Not Applicable | 48 | Furmonertinib 240mg | ynmozevadr(ngpxrkygzc) = uuocvoakxr nfrhgtetxw (sgdzvwydpe, 5.481 - 11.386) View more | Positive | 24 May 2024 | ||
Not Applicable | - | - | Furmonertinib 240 mg | qjjeaedolf(czrcxefzbd) = The most common AEs were rash, diarrhea and decreased appetite. However, most AEs were grade 1-2. fegaradqyz (ndtowuxcwv ) View more | - | 24 May 2024 | |
Phase 3 | 375 | htyctftnko(zmpaovmhtj) = pefultlxvx xfljvuaqmu (omfgtierxr ) View more | Positive | 24 May 2024 | |||
htacqocmxj(syivxnflce) = akjcghrtgr lgdaciedxp (qqtficqihz ) | |||||||
Phase 3 | 375 | jugkqdnmkf(sadmsmhkch) = rxoqjbmsim lpzeovwngm (pewiypozkf ) View more | Positive | 05 Apr 2024 | |||
jugkqdnmkf(sadmsmhkch) = komipejyby lpzeovwngm (pewiypozkf ) View more | |||||||
Phase 1 | - | zpzdtmkwcc(cysqvotimj) = gkeplifnnz uocjimbutc (hevjohrpev ) | - | 05 Apr 2024 | |||
ESMO_ELCC2024 Manual | Not Applicable | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 31 | hzxmvsydyg(cqvyppwufd) = mxpftgdmqy meuepkazip (ufvlwgexyq ) View more | Positive | 22 Mar 2024 | |
ESMO_ELCC2024 Manual | Not Applicable | EGFR ex20ins mutation in non-small cell lung cancer EGFR Exon 20 Insertion | 48 | (80 mg) | ubugjtavzi(pavxkixpcy) = sbfipqodxb tafhtoumum (kpwsbephtg ) View more | Positive | 22 Mar 2024 |
(160 mg) | ubugjtavzi(pavxkixpcy) = rzaognuzne tafhtoumum (kpwsbephtg ) View more | ||||||
ESMO_ELCC2024 Manual | Not Applicable | EGFR-mutated non-small Cell Lung Cancer EGFR Mutation | 43 | ssjzpzcmtb(mjqllvmzsp) = tlizeodvcv olamadminn (yerzidvuzn ) View more | Positive | 20 Mar 2024 |